1. Home
  2. CALX vs TRVI Comparison

CALX vs TRVI Comparison

Compare CALX & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Calix Inc

CALX

Calix Inc

N/A

Current Price

$36.71

Market Cap

2.3B

ML Signal

N/A

Logo Trevi Therapeutics Inc.

TRVI

Trevi Therapeutics Inc.

N/A

Current Price

$13.48

Market Cap

1.9B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CALX
TRVI
Founded
1999
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.3B
1.9B
IPO Year
2009
2019

Fundamental Metrics

Financial Performance
Metric
CALX
TRVI
Price
$36.71
$13.48
Analyst Decision
Buy
Strong Buy
Analyst Count
7
11
Target Price
★ $62.33
$28.18
AVG Volume (30 Days)
917.3K
★ 2.6M
Earning Date
11-02-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 157.78
31.91
EPS
★ 0.42
N/A
Revenue
★ $510,367,000.00
N/A
Revenue This Year
$19.15
N/A
Revenue Next Year
$15.63
N/A
P/E Ratio
$90.89
★ N/A
Revenue Growth
★ 11.24
N/A
52 Week Low
$32.35
$9.82
52 Week High
$69.73
$20.22

Technical Indicators

Market Signals
Indicator
CALX
TRVI
Relative Strength Index (RSI) 51.77 49.73
Support Level $34.70 $13.08
Resistance Level $41.02 $13.55
Average True Range (ATR) 1.10 0.60
MACD 0.16 0.27
Stochastic Oscillator 43.84 76.06

Price Performance

Historical Comparison
CALX
TRVI

About CALX Calix Inc

Calix Inc develops, markets and sells its appliance-based platform, cloud and managed services that enable service providers of all types and sizes to innovate and transform their businesses. The company's customers utilize the real-time data and insights from Calix platforms to simplify their business and deliver experiences that excite their subscribers. The resulting growth in subscriber acquisition, loyalty and revenue creates more value for their businesses and communities. The Company's revenue is principally derived in the United States and it also has its presence in Europe, Americas excluding U.S., and Rest of World.

About TRVI Trevi Therapeutics Inc.

Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.

Share on Social Networks: